1. Is Aurobindo Pharma Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Aurobindo Pharma Ltd is a good quality company.
2. Is Aurobindo Pharma Ltd undervalued or overvalued?
The key valuation ratios of Aurobindo Pharma Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Aurobindo Pharma Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Aurobindo Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||12.9%||22.2%||20.9%||17.4%||14.9%||14.5%||11.1%||11.6%||16.4%||7.2%||-|
|Value Creation Index ⓘ||-0.1||0.6||0.6||0.6||0.3||0.3||-0.0||0.0||0.5||NA||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||31.1%||13.8%||13.2%||4.8%||6.9%||19.4%||9.1%||18.4%||-28.7%||-|
|Adj EPS ⓘ||9.2||20.6||26.4||26.6||28.2||30.5||25.2||29.3||50.9||23.7||24.8|
|YoY Gr. Rt. %||-||124.6%||27.7%||0.8%||6%||8.2%||-17.4%||16.3%||73.9%||-53.4%||-|
|BVPS (₹) ⓘ||50.5||68.8||91.8||117.3||144||170.4||193.7||222.8||271.8||292.2||292.1|
|Adj Net Profit ⓘ||535||1,203||1,538||1,554||1,650||1,786||1,474||1,715||2,983||1,391||1,455|
|Cash Flow from Ops. ⓘ||625||328||590||1,185||2,457||922||530||2,201||2,995||3,727||-|
|Debt/CF from Ops. ⓘ||4.5||8.9||5.6||3.5||1.2||4||8.5||1.7||1.3||0.5||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||11.1%||-3.4%||-1.9%||-53.4%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||19.7||34.6||32.8||25.4||21.6||19.4||13.8||14.1||20.6||8.4||8.5|
|Op. Profit Mgn % ⓘ||19||28.2||28.5||27.3||24.9||26.2||19.7||20.2||26||13.2||13.1|
|Net Profit Mgn % ⓘ||9.9||16.9||19||17||17.2||17.4||12||12.8||18.9||12.3||12.9|
|Debt to Equity ⓘ||1||0.7||0.6||0.6||0.4||0.4||0.4||0.3||0.3||0.1||0|
|Working Cap Days ⓘ||229||235||273||284||278||288||294||306||290||402||308|
|Cash Conv. Cycle ⓘ||130||121||159||181||179||182||189||200||177||222||177|
No data to display
Return on Equity has declined versus last 3 years average to 8.50%
Sales growth has been subdued in last 3 years -2.71%
Net Profit has been subdued in last 3 years -1.94%
Sales growth is not so good in last 4 quarters at -27.21%
|TTM EPS (₹)||24.8||45.2|
|TTM Sales (₹ Cr.)||11,287||23,455|
|BVPS (₹.) ⓘ||292.1||419.4|
|Reserves (₹ Cr.) ⓘ||17,059||24,517|
|From the Market|
|52 Week Low / High (₹)||503.40 / 929.20|
|All Time Low / High (₹)||0.56 / 1063.75|
|Market Cap (₹ Cr.)||33,314|
|Equity (₹ Cr.)||58.6|
|Face Value (₹)||1|
|Industry PE ⓘ||39.4|
Aurobindo Pharma commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. The company became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillin’s, it has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics. Through cost effective manufacturing capabilities and a few loyal customers, the company also entered the high margin specialty generic formulations segment. Today, it has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries. The formulation business is systematically organized with a divisional structure, and has a focused team for key international markets. The company’s units for APIs / intermediates and units for formulations are designed to meet the requirements of both advanced as well as emerging market opportunities.
A well-integrated pharma company, the company features among the top 2 Pharmaceutical companies in India in terms of consolidated revenues. Aurobindo exports many countries across the globe with around 90% of revenues derived from international operations. Its customers include premium multi-national companies. With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. It is among the largest filers of DMFs and ANDAs in India.
Business area of the company
Aurobindo Pharma continues to be one of the world’s fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration. Its API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market. It has built a strong presence in key therapeutic segments such as Central nervous system (CNS), cardiovascular (CVS), anti-retroviral (ARV), anti-diabetics, gastroenterology and antibiotics. Also, it is building a diversified pipeline in high-margin specialty generic formulations segment.
Awards & Accolades
Major Events and Milestones